Pfizer ends COVID-19 vaccine trial with a 95% success rate
(Reuters) - Pfizer Inc PFE.N and BioNTech BNTX.O could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.
The efficacy of the shot was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately affected the elderly and certain groups including Black people.
The U.S. Food and Drug Administration could grant emergency-use approval towards the end of the first half of December or early in the second half, BioNTech Chief Executive Ugur Sahin told Reuters TV. Conditional approval in the European Union could be secured in the second half of December, he added.
“If all goes well I could imagine that we gain approval in the second half of December and start deliveries before Christmas, but really only if all goes positively,” he said.
The success rate of the vaccine developed by U.S. firm Pfizer and Germany’s BioNTech is the highest of any candidate in late-stage clinical trials so far, and experts said it was a significant achievement in the race to end the pandemic.
Pfizer said 170 volunteers in its trial involving over 43,000 people contracted COVID-19 but 162 of them had only been given a placebo, meaning the vaccine was 95% effective. Of the 10 people who had severe COVID-19, one had received the vaccine.
“A first in the history of mankind: less than a year from the sequence of the virus to the large-scale clinical trial of a vaccine, moreover based on a whole new technique,” said Enrico Bucci, a biologist at Temple University in Philadelphia. “Today is a special day.”
BioNTech’s Sahin said the U.S. emergency authorization would be applied for on Friday.
The FDA committee tentatively plans to meet on Dec. 8-10, a source familiar with the situation said, though the dates could still change.
The FDA did not respond to requests for comment.